

ALLEGED SHIPMENT: On or about October 6 and 20 and December 8, 1952, by Fellows Medical Mfg. Co., Inc., from New York, N. Y.

PRODUCT: 1 1,000-capsule bottle and 55 50-capsule bottles of *vitamin B complex capsules* at Cleveland, Ohio.

LABEL, IN PART: "Fellows Vitamin B-Complex Capsules each capsule contains Thiamine Hydrochloride (10 M. D. R.) 10 Mg. * * * Therapeutic."

NATURE OF CHARGE: Adulteration, Section 501 (c), the strength of the article differed from that which it purported or was represented to possess, namely, 10 milligrams of thiamine hydrochloride (vitamin B₁) per capsule.

Misbranding, Section 502 (a), the label statement "each capsule contains Thiamine Hydrochloride (10 M. D. R.) 10 Mg." was false and misleading as applied to the article, which contained less than that amount of thiamine hydrochloride (vitamin B₁) per capsule.

DISPOSITION: February 18, 1953. Default decree of condemnation and destruction.

3995. Adulteration and misbranding of isopropyl alcohol rubbing compound.

U. S. v. 200 Cases * * *. (F. D. C. No. 34459. Sample No. 44824-L.)

LIBEL FILED: December 23, 1952, District of Connecticut.

ALLEGED SHIPMENT: On or about October 29 and November 13, 1952, by S. T. Brill Co., Inc., from Brooklyn, N. Y.

PRODUCT: 200 cases, each containing 12 16-ounce bottles, of *isopropyl alcohol rubbing compound* at New Haven, Conn. Examination showed that the product contained 63.6 percent isopropyl alcohol.

LABEL, IN PART: (Bottle) "Clifton Isopropyl Alcohol Rubbing Compound."

NATURE OF CHARGE: Adulteration, Section 501 (b), the article purported to be and was represented as a drug, "Isopropyl Alcohol Rubbing Compound," the name of which is recognized in the National Formulary, an official compendium, and its strength differed from the standard set forth in such compendium since it contained less than 68 percent isopropyl alcohol.

Misbranding, Section 502 (a), the label statement "Isopropyl Alcohol 70% By Volume" was false and misleading as applied to the product, which contained less than 70 percent isopropyl alcohol.

DISPOSITION: February 13, 1953. S. T. Brill Co., Inc., Brooklyn, N. Y., claimant, having consented to the entry of a decree, judgment of condemnation was entered and the court ordered that the product be released under bond for reprocessing under the supervision of the Federal Security Agency.

3996. Adulteration and misbranding of adhesive strips. U. S. v. 60 Cartons * * *.

(F. D. C. No. 34624. Sample No. 57478-L.)

LIBEL FILED: On or about January 27, 1953, District of Maryland.

ALLEGED SHIPMENT: On or about December 17, 1952, by the Sanette Mfg. Co., from New Rochelle, N. Y.

PRODUCT: 60 cartons, each containing 12 packages, of *adhesive strips* at Baltimore, Md.

LABEL, IN PART: (Retail package unit) "Sanette 12 Sterilized Waterproof Adhesive Strips."

NATURE OF CHARGE: Adulteration, Section 501 (b), the article purported to be a drug, "Adhesive Absorbent Gauze [or "Adhesive Absorbent Compress"],"

the name of which is recognized in the United States Pharmacopeia, an official compendium, and its quality and purity fell below the official standard since the standard provides that "Adhesive Absorbent Gauze [or "Adhesive Absorbent Compress"]" must be sterile, whereas the article was not sterile but was contaminated with living micro-organisms.

Misbranding, Section 502 (a), the label statement "Sterilized" was false and misleading.

DISPOSITION: February 20, 1953. Default decree of condemnation and destruction.

DRUGS ACTIONABLE BECAUSE OF FALSE AND MISLEADING CLAIMS*

3997. Misbranding of Panrein tablets, Panbile tablets, Ioquasol tablets, Noodor tablets, Nokof tablets, and Thiekla. U. S. v. 3 Bottles, etc. (F. D. C. No. 34651. Sample Nos. 46652-L to 46655-L, incl., 46657-L, 46658-L.)

LABEL FILED: February 9, 1953, Southern District of Texas.

ALLEGED SHIPMENT: On various dates during the latter part of 1952 and the early part of 1953, by John C. Thie (TPCS Distributors), from Pasadena, Calif.

PRODUCT: 3 90-tablet bottles of *Panrein tablets*, 3 90-tablet bottles of *Panbile tablets*, 4 90-tablet bottles of *Ioquasol tablets*, 3 90-tablet bottles of *Noodor tablets*, 2 40-tablet bottles of *Nokof tablets*, and 4 2-ounce jars of *Thiekla* at Houston, Tex., together with an accompanying booklet entitled "A New Approach to Therapy [Anat]."

LABEL, IN PART: (Bottle) "Formula I Panrein 90 tablets (1-wv) Each Tablet Contains: Barosma 65.0 Mg. Bear Berry 64.4 Mg. Couch Grass 66.2 Mg. Alfalfa 63.6 Mg. In a base of parsley and other inert filler," "Formula III Panbile 90 Tablets (3-WW) Each Enteric coated tablet contains: Pancreatin USP 259.2 Mg. Bile Salts (Ext. Ox Bile) 129.6 Mg. Dehydrocholic Acid 21.6 Mg. In desiccated protein and other excipients," "Formula 2 Ioquasol 90 Tablets (2 WV) Each enteric coated tablet contains: Iodine 30.2 mg. Combined and proportioned by a special process making a water soluble iodine compound—Ioquasol," "Formula XVII Noodor 90 Tablets (17-2W) Each tablet contains excipients and Chlorophyll which are completely water soluble," "Formula XXV Nokof 40 Tablets (25-W) Each tablet Contains: P. E. Licorice Root 32 mg., ester of Para-Amino-Benzoic acid 12 mg. (one of the Vitamin B Complex Factors); in a base containing Peppermint (ext.), Anise, and excipients," and (jar) "Formula V Thiekla (5-W) Contains: Oxides, Chlorides, Sulphates, Nitrates, and Carbonates, of Ca, Fe, Mg, Na, K, H, N, I, and other Colloidal minerals normally found in the human body."

NATURE OF CHARGE: Misbranding, Section 502 (a), certain statements in the above-mentioned booklet were false and misleading since the articles were not adequate and effective treatments for the conditions and purposes represented and suggested. The statements represented and suggested:

That the *Panrein tablets* were an adequate and effective treatment for improving health, stopping the death process, maintaining normal health, dropsy, inflamed condition of the urinary organs, nervousness, irritable bladder, cystitis, diseases of the urinary tract, gravel, chronic catarrh of the bladder, morbid irritation of the bladder and urethra, diseases of the prostate, urinary

*See also Nos. 3981, 3985, 3986, 3988, 3989, 3992-3996.